Methods of secretory vimentin detection and modulation

• US 7,691,582 B2
• Filed: 09/24/2003
• Issued: 04/06/2010
• Est. Priority Date: 09/27/2002
• Status: Expired due to Fees

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Markovitz, David M., Punturieri, Antonello, Mor-Vaknin, Nirit
• Primary Examiner(s): Cook; Lisa V
• Application Number:
  US10/670,065
• Publication Number:
  US 20040121419A1
• Time in Patent Office: 2,386 Days
• Field of Search: 435/7.1, 435/7.2, 435/7.32, 435/325, 436/501, 424/130.1
• US Class Current: 435/7.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C12Q 1/18 Testing for antimicrobial activity of a material
• CPC Class Codes: G01N 2500/02 Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
• CPC Class Codes: G01N 33/6887 from muscle, cartilage or connective tissue

Abstract

The present invention relates to methods for screening and modulating the bioavailability of extracellular secretory vimentin. In particular, the present invention provides inhibitors and activators of secretory vimentin including antibodies, small interfering RNAs, and antisense oligonucleotides. The present invention thus provides novel drug targets for enhanced anti-microbial response, and methods of using such modulators to beneficially alter the pathophysiologic effects of secretory vimentin.

Claims

1. A method for reducing the risk of mortality associated with a pathogen in a subject, comprising:

a) providing;

i) a subject having said pathogen; and

ii) an anti-vimentin antibody that binds to vimentin and inhibits vimentin activity; and

b) administering said anti-vimentin antibody to said subject having said pathogen under conditions such that said administering reduces the risk of mortality associated with said pathogen.

2. The method of claim 1, wherein said pathogen is a bacterial pathogen.

3. The method of claim 1, wherein said anti-vimentin antibody comprises a monoclonal antibody.

4. The method of claim 1, wherein said anti-vimentin antibody comprises a polyclonal antibody.

5. The method of claim 1, wherein said subject is a human subject.

6. The method of claim 1, wherein said antibody is a humanized antibody.

7. The method of claim 1, wherein said administration is parenteral administration.

8. The method of claim 1, wherein said subject having said pathogen has sepsis.

9. The method of claim 2, wherein said bacterial pathogen is E. coli.